嗨，吃热的－kun

[zhutiger]

作者: ike

成交量快到昨天的，还有４8分钟，再放５万股，就８.18了
3:12

不懂?

Another 2.65 million shares were immediately listed as being for resale by selling shareholders. It was not clear from reports whether these shares had been placed. After the IPO, 19.5 million shares of Shenghuo are outstanding.






Seeking Alpha
China Shenghuo Pharmaceutical Doubles After Its IPO
Monday June 18, 7:47 am ET

ChinaBio Today submits: China Shenghuo Pharmaceutical Holdings, Inc. (AMEX: KUN - News) listed its shares on the American Stock Exchange on Thursday, June 14, after completing a very small, 400,000-share IPO that seems more like a private placement. The shares were priced at $3.50, led by the sole underwriter: WestPark Capital in Los Angeles.

ADVERTISEMENT
WestPark was instrumental in forming the company in 2005.

Another 2.65 million shares were immediately listed as being for resale by selling shareholders. It was not clear from reports whether these shares had been placed. After the IPO, 19.5 million shares of Shenghuo are outstanding.

Among other activities for China Shenghuo, West Park brokered a private placement in 2005 of 2 million shares at $.90 each ($1.8 million gross proceeds), of which almost $200,000 went to West Park for its work.

Perhaps because of the small float, Shenghuo fared very well – in fact excellently – in open market trading. After opening at $4.40 on Thursday afternoon, the shares doubled over the IPO price in the next day and a half of trading. At the close on Friday, June 14, Shenghuo stood at an even $7.00, up $2.27 or 49% on the day. At 208,000 shares traded, volume was not particularly high, though that was just over 50% of the shares sold in the IPO. At $7 per share, the market is giving Shenghuo a value of $137 million.

In 2006, China Shenghuo made a profit of $3.6 million on $20 million of revenue. That works out to 17 cents per share.

In terms of business, China Shenghuo was formed in 1995. It combines traditional Chinese medicines with western pharmacology, building pharmaceutical, nutritional and cosmetic product lines around Panax notoginseng, a form of ginseng that invigorates and builds blood. A full 80% of its revenues come from Xuesaitong Soft Capsules, which are given to treat cardiovascular and cerebrovascular disease. It has a total of 31 state-approved medications. Almost all of its sales are in China, though small amounts of its drugs are exported to other countries in Asia.

[zhutiger]

同样是中药股, 同样是高成长. 为什么TCM是１５倍市赢率，　而ＫＵＮ　可以是２９．
我看不懂，　就因为盘子小？　我还是安心持有我的TCM. 　

以下我也看不懂?

Another 2.65 million shares were immediately listed as being for resale by selling shareholders. It was not clear from reports whether these shares had been placed. After the IPO, 19.5 million shares of Shenghuo are outstanding.

个人意见, 仅供参考.

[zhutiger]

从YAHOO上看
Market Cap: 114.33M

114.33/6=19.05Million
应该有１９ＭＩＬＬＩＯＮ在流通.

[zhutiger]

作者: 股市小兵

刚才查了一下http://stocks.us.reuters.com/stocks/...asp?symbol=kun. EPS=0.21而TCM只有0.19.
坚定持股信心!!!

兄弟, 提醒一下. 1 个TCM ADR = 4 TCM SHARES.
所以TCM 业绩是0.19*4.
KUN 我就不知道了.

[zhutiger]

作者: zhutiger

同样是中药股, 同样是高成长. 为什么TCM是１５倍市赢率，　而ＫＵＮ　可以是２９．
我看不懂，　就因为盘子小？　我还是安心持有我的TCM. 　

以下我也看不懂?

Another 2.65 million shares were immediately listed as being ...

有分险吧. IKE 推荐的TCM, SDTH 我敢跟, 这个还是太高了. 盘子小的只适合短线及中国的投机市.
不然MM拉起来, 谁接?
不过现在也跌的差不多了. 再减也无很大意义.